Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 66Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Mantle-Cell 10Lymphoma 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 7Neoplasms, Plasma Cell 6Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Smoldering Multiple Myeloma 3Neoplasms 3Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hematologic Diseases 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1

Interventions

Specimen Handling 6pembrolizumab 4enfortumab vedotin 4Magnetic Resonance Spectroscopy 4Gemcitabine 3cabozantinib 2Nivolumab 2Carboplatin 2Biopsy 2relatlimab 1eribulin 1erdafitinib 1avelumab 1atezolizumab 1Watchful Waiting 1Standard of Care 1Practice Guidelines as Topic 1Plasmapheresis 1Plasma Exchange 1Observation 1Lenalidomide 1Ipilimumab 1Doxorubicin 1Cystoscopy 1Contrast Media 1Cisplatin 1Central Venous Catheters 1CTLA-4 Antigen 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Lenalidomide × 90 days × Clear all
NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡